Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

4628 - Gastric cancer screening in BRCA 2 gene mutation carriers: should it be recommended?

Date

29 Sep 2019

Session

Poster Display session 2

Topics

Tumour Site

Gastric Cancer

Presenters

Inês Oliveira

Citation

Annals of Oncology (2019) 30 (suppl_5): v253-v324. 10.1093/annonc/mdz247

Authors

I.C. Oliveira1, S. Fernandes2, P. Pereira1, S. Fragoso3, S. Santos4, P. Rodrigues5, J. Parreira5, P. Louro5, I. Coelho5, F. Rodrigues5, A. Clara6, A. Luís6, F. Vaz6

Author affiliations

  • 1 Oncologia Médica, Instituto Portuguès de Oncologia de Lisboa Francisco Gentil, E.P.E., 1099-023 - Lisbon/PT
  • 2 Genética, Centro Hospitalar Universitário de Coimbra, Coimbra/PT
  • 3 Vipm, Instituto Portuguès de Oncologia de Lisboa Francisco Gentil, E.P.E., 1099-023 - Lisbon/PT
  • 4 Clínica De Risco Familiar; Unidade De Investigação Em Patobiologia Molecular;, Instituto Portuguès de Oncologia de Lisboa Francisco Gentil, E.P.E. (IPOLFG EPE), 1099-023 - Lisbon/PT
  • 5 Clinica De Risco Familiar, Instituto Portuguès de Oncologia de Lisboa Francisco Gentil, E.P.E., 1099-023 - Lisbon/PT
  • 6 Oncologia Médica, Clinica De Risco Familiar, Instituto Portuguès de Oncologia de Lisboa Francisco Gentil, E.P.E., 1099-023 - Lisbon/PT

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4628

Background

Gastric cancer (GC) risk is associated with Tp53 and ATM mutations but the inclusion of GC in the BRCA2 phenotype is still controversial due to confounding risk factors. Because of the high incidence of GC in Portugal and as 2/3 of all our HBOC families are BRCA2, to include or not GC surveillance in prospective follow up is of utmost importance. The objective of this study is to characterize GC diagnoses observed in a prospective cohort of BRCA1/2, Tp53 and ATM carriers to gain insight for future studies.

Methods

Review of all GC diagnoses in BRCA1/2, TP53 and ATM carriers under prospective surveillance and analysis of family data regarding GC.

Results

Data from 830 pts, 723 with a confirmed genetic diagnosis (BRCA2-488, BRCA1-205 Tp53-15, ATM-14, BRCA1/2-1pt) belonging to 534 non-related families (BRCA2-325, BRCA1-187, Tp53-12, ATM-9, both BRCA1/2-1) was reviewed. GC was reported in 15 BRCA1 (8%), 52 BRCA2 (16%), 4 ATM (44%) and 4 Tp53 (33%) families. More than 1 GC case was reported in 20%, 12%, 50%, 25% of BRCA1, BRCA2, ATM and Tp53 families, respectively. Pathological confirmation was available in 12 pts: 10 BRCA2 (2 GEJ, 60% male, median age at diagnosis 59,4 yrs), 1 ATM (male, 74 yrs), 1 p53 (female, 42 yrs). Pathology: 5 intestinal type, 2 signet ring cells, 4-other (including 1 NE tumor). Only five of 12 pts had GC as the only neoplastic diagnosis. For a median follow up of 39 months, 5 pts (42%) are alive, only 2 without relapse. Only 1 pt with signet ring cell GC was submitted to CT and an objective response was observed. GC was the cause of 71% of deaths.

Conclusions

Confirmed GC in BRCA2 carriers revealed a high morbidity and mortality. Unexpected response to platin therapy was observed in a signet ring cell case. Since management of BRCA2 carriers include measures that impact on survival, clarification of BRCA2 association with GC is necessary for better prospective surveillance plans, and eventually personalized therapeutic approaches.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.